Ref ID: 19279
Author:
L. Gregson, J. Goodwin, A. Johnson, L. McEntee, C. B. Moore, M. Richardson, W. W. Hope, S. J. Howard
Author address:
Univ. of Liverpool, Liverpool, UNITED KINGDOM; Univ. Hosp. of South Manchester, Manchester, UNITED KINGDOM.
Full conference title:
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy
Date: 10 September 2014
Abstract:
ackground: Triazoles are first-line agents for treatment of aspergillosis. The prevalence of triazole resistance in Aspergillus fumigatus is increasing. The extent of cross-resistance between triazole agents is poorly defined. Isavuconazole is a triazole currently being studied in phase III clinical trials. The in vitro susceptibility of isavuconazole against non-wild-type strains of A. fumigatus is not well characterized. Methods: Forty clinical A. fumigatus isolates, the majority of which had elevated MICs to at least one triazole, and had a putative molecular mechanism of resistance defined, were tested for susceptibility using CLSI methodology. The following compounds were tested: amphotericin B, itraconazole, voriconazole, posaconazole, and isavuconazole. Results: Thirty-one strains had triazole MICs above the wild-type range. All had high (>8 mg/L) itraconazole MICs, of which 77% (24/31) and 68% (21/31) had raised posaconazole and voriconazole MICs respectively. Isolates with raised triazole MICs had higher isavuconazole MICs. Specifically, isavuconazole MICs mirrored changes in voriconazole susceptibility (Spearman’s correlation coefficient 0.885, P<0.001). Isolates with cyp51A alterations at codons 98, 138, 431, 434 and 448 revealed a pan-azole resistant phenotype, including raised isavuconazole MICs. Isavuconazole MICs tended to be lower in isolates with substitutions at position 54. In contrast, isavuconazole MICs were more variable, and were more likely to be raised, in isolates with M220 alterations. Conclusions: Isavuconazole MICs were more likely to be raised in strains with reduced susceptibility to other triazoles, and tended to mirror changes in voriconazole susceptibility. The extent to which this reduced in vitro susceptibility has an impact on clinical care remains to be established.
Abstract Number: NULL
Conference Year: 2013
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a